View Older Stories View More Recent Stories

May 2, 2025 05:52AM Citizens JMP Reiterates Market Outperform Rating on Cytokinetics (CYTK)
May 1, 2025 04:17PM Cytokinetics (CYTK) Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy
Apr 24, 2025 04:17AM Barclays Starts Cytokinetics (CYTK) at Overweight
Apr 22, 2025 07:04AM H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
Apr 21, 2025 09:53AM H.C. Wainwright on Cytokinetics (CYTK): 'Less Restrictive Label for Camzyos in oHCM; We Still Project Cleaner Label for Aficamten; Reiterate Top Pick'
Apr 21, 2025 08:01AM Stifel Reiterates Buy Rating on Cytokinetics (CYTK)
Apr 15, 2025 05:23AM Cytokinetics (CYTK) PT Lowered to $54 at BofA Securities
Apr 15, 2025 04:10AM Citizens JMP Reiterates Market Outperform Rating on Cytokinetics (CYTK)
Apr 11, 2025 09:44AM Piper Sandler: 'What Biotech Names to Own in Market Volatility'
Apr 10, 2025 04:06AM Citizens JMP Reiterates Market Outperform Rating on Cytokinetics (CYTK)
Apr 4, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
Apr 3, 2025 07:33AM Cantor Fitzgerald Reiterates Overweight Rating on Cytokinetics (CYTK)
Apr 3, 2025 04:07AM Citizens JMP Reiterates Market Outperform Rating on Cytokinetics (CYTK)
Apr 2, 2025 01:46PM Raymond James Reiterates Outperform Rating on Cytokinetics (CYTK), PT $81
Apr 2, 2025 09:22AM Morgan Stanley Reiterates Overweight Rating on Cytokinetics (CYTK)
Mar 20, 2025 07:31AM Cytokinetics (CYTK) Announces Launch of EARTH-HCM
Mar 18, 2025 06:40AM H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
Mar 10, 2025 09:40AM Citi Reiterates Buy Rating on Cytokinetics (CYTK)
Mar 10, 2025 07:41AM Cytokinetics (CYTK): FDA has informed Cytokinetics that it does not plan to convene an advisory committee meeting to review the Company’s NDA for aficamten
Mar 7, 2025 09:46AM Morgan Stanley Assumes Cytokinetics (CYTK) at Overweight (Yesterday)
Feb 27, 2025 04:03PM Cytokinetics (CYTK) Misses Q4 EPS by 4c, provides guidance
Feb 18, 2025 07:21AM Stifel Reiterates Buy Rating on Cytokinetics (CYTK)
Feb 14, 2025 01:30PM Cytokinetics (CYTK) mentioned at Betaville
Feb 13, 2025 03:30AM Morgan Stanley Upgrades Cytokinetics (CYTK) to Overweight
Feb 11, 2025 07:30AM Cytokinetics (CYTK) Appoints Robert E. Landry to its Board
Feb 7, 2025 06:50AM Citi Starts Cytokinetics (CYTK) at Buy, PT $86
Feb 7, 2025 04:34AM JMP Securities Reiterates Market Outperform Rating on Cytokinetics (CYTK)
Jan 30, 2025 07:31AM Cytokinetics (CYTK) Announces Recipients of Its Seventh Annual Communications Grant Program
Jan 29, 2025 09:12AM Cantor Fitzgerald provides update on Biotechnology stocks
Jan 21, 2025 04:07PM Stifel Starts Cytokinetics (CYTK) at Buy
Jan 21, 2025 07:31AM Cytokinetics (CYTK) Announces Start of AMBER-HFpEF
Jan 14, 2025 06:45AM H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
Jan 13, 2025 12:50PM RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
Jan 3, 2025 12:45PM Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm
Jan 3, 2025 08:23AM Piper Sandler Explores Direct and Indirect Catalysts for Selected Biotechnology Companies
Dec 23, 2024 07:32AM Cytokinetics (CYTK) Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
Dec 20, 2024 02:09PM Cytokinetics (CYTK) Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
Dec 18, 2024 07:26AM Cytokinetics (CYTK) PT Raised to $82 at RBC Capital Following Bayer Partnership
Dec 3, 2024 06:59AM H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
Dec 2, 2024 07:31AM Cytokinetics (CYTK) Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
Nov 19, 2024 12:38PM Goldman Sachs Reiterates Neutral Rating on Cytokinetics (CYTK)
Nov 18, 2024 07:32AM H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
Nov 11, 2024 07:32AM Cytokinetics (CYTK) Announces Initiation of Phase 1 Clinical Study of CK-4015089
Nov 6, 2024 04:01PM Cytokinetics (CYTK) Misses Q3 EPS by 13c
Oct 18, 2024 06:53AM Mizuho Reiterates Outperform Rating on Cytokinetics (CYTK)
Oct 17, 2024 06:53AM H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
Oct 17, 2024 06:18AM Truist Securities Reiterates Buy Rating on Cytokinetics (CYTK)
Oct 9, 2024 07:20AM Cytokinetics (CYTK) PT Raised to $120 at H.C. Wainwright
Oct 1, 2024 06:56AM H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
Sep 30, 2024 07:24AM H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
View More Recent Stories View Older Stories